MalignanciesLymphomaMultiple MyelomaRefractoryChronic lymphocytBenefit for patients with lymphoidNeoplasmsMalignancyTissuesOncologyMalignantTrialsCancersImmunologyMyeloidBonePatients with chronic lymphocyPathogenesisAntigenReactivePeripheral bloodInhibitorsCentreLociRituximabHematopoieticSurvivalMarkersNeoplasmCellsHeterogeneityTreatmentsPrognosticLymphocytesPracticeHematologyMonoclonalPhaseBiopsiesPotentTreatmentMolecularLaboratory
Malignancies21
- The clinical success of the BCL-2-selective BH3-mimetic venetoclax in patients with poor prognosis chronic lymphocytic leukemia (CLL) highlights the potential of targeting the BCL-2-regulated apoptotic pathway in previously untreatable lymphoid malignancies. (rti.org)
- Venetoclax is active in other lymphoid malignancies including several B cell non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, with the highest intrinsic sensitivity observed in mantle cell lymphoma and Waldenstrom macroglobulinemia. (biomedcentral.com)
- TdT is a nuclear enzyme expressed by immature lymphoid malignancies, but the expression pattern of this marker is not well characterized in the skin. (karger.com)
- This timely new reference integrates the latest clinical results and laboratory studies on the resistance of specific cancers to chemotherapeutic drugs-covering drug resistance in lung, breast, ovary, and colon cancer as well as hematological malignancies. (routledge.com)
- It encompasses nearly 40 different types of lymphoid malignancies broadly divided into Hodgkin and non-Hodgkin categories. (arizona.edu)
- Lymphoid malignancies are cancers of immune cells that have been transformed to grow out of control. (rochester.edu)
- We propose to utilize these xenograft models to study the critical microenvironment cells and factors required for growth and survival of lymphoid malignancies. (rochester.edu)
- Our long-term goal is to apply these studies toward the identification of unique cell subpopulations and factors in the local tumor microenvironment of lymphoid malignancies that will aid in the diagnosis and treatment of these cancers. (rochester.edu)
- Additionally, we aim to advance a laboratory model of the local tumor microenvironment that will accelerate testing of therapeutic drug candidates to promote rapid clinical benefit for patients with lymphoid malignancies. (rochester.edu)
- It is also the prototype of B-cell chronic lymphoid malignancies and of their ramifications within the fields of hematology, immunology and oncology. (epa.gov)
- For a long time the Cinderella of lymphoid malignancies CLL has now become the focus of major interest and an increasing number of investigators from different areas, including genetics, molecular biology, basic and applied immunology are becoming actively engaged in the investigation of CLL. (epa.gov)
- BRUKINSA is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. (financialcontent.com)
- We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. (ashpublications.org)
- B-cell malignancies, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia afflict more than one hundred and fifty thousand patients in the seven major markets each year. (rdworldonline.com)
- The research team believes that the LYNX panel is suitable for routine testing with research and clinical applicability and may assist in personalized management of patients with lymphoid malignancies. (ceitec.eu)
- The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. (mboum.com)
- SEATTLE , Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ ® assay technology across the company's pipeline of treatments for patients with lymphoid malignancies. (adaptivebiotech.com)
- MRD assessment is playing a growing role in clinical trials for lymphoid malignancies by providing an early measure of treatment response and serving as a potential endpoint, which may enable novel therapies to be made available to patients sooner. (adaptivebiotech.com)
- As part of the collaboration, MRD status based on Adaptive's clonoSEQ assay may be used as an endpoint in certain clinical trials to assess the depth and duration of response to BeiGene's investigational medicines in patients with lymphoid malignancies. (adaptivebiotech.com)
- Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by the clonoSEQ assay in patients diagnosed with CLL, MM, ALL and DLBCL. (adaptivebiotech.com)
- Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study. (myeloma.org.uk)
Lymphoma34
- If enlarged lymph nodes are caused by infiltrating CLL-type cells, a diagnosis of small lymphocytic lymphoma (SLL) is made. (wikipedia.org)
- CLL can be grouped with small lymphocytic lymphoma (SLL) as one disease with two clinical presentations. (wikipedia.org)
- Chronic lymphocytic leukemia may also develop a Richter's transformation i.e. conversion to a far more aggressive form that has the histopathology of diffuse large B cell lymphoma or Hodgkin's lymphoma. (wikipedia.org)
- CLL has also been reported to convert into other more aggressive diseases such as lymphoblastic lymphoma, hairy cell leukemia, high grade T cell lymphomas, acute myeloid leukemia, lung cancer, brain cancer, melanoma of the eye or skin, salivary gland tumors, and Kaposi's sarcomas. (wikipedia.org)
- Dr. Connors is best known for his clinical investigations into the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemias and multiple myeloma. (genomebc.ca)
- Dr. Gerrie is involved in translational, clinical trial and outcomes-based research related to leukemia and lymphoma. (bccrc.ca)
- Other academic interests include the investigation of novel therapeutics and stem cell transplant for chronic lymphocytic leukemia (CLL) and lymphoma and improving long-term outcomes for lymphoma and stem cell transplant survivors. (bccrc.ca)
- Innovative Leukemia and Lymphoma Therapy provides a complete and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma that are being introduced in the clinic today. (routledge.com)
- Adult Burkitt leukemia and lymphoma. (medscape.com)
- Lymphoid neoplasms include lymphoma, chronic lymphocytic leukemia, and multiple myeloma. (arizona.edu)
- The diagnosis of lymphoma and its type can be suspected based on clinical history, laboratory data, or imaging studies. (arizona.edu)
- This enabled identification of TFs that can be uniquely associated to the tumor cells of chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), hairy cell leukemia (HCL), and mantle cell lymphoma (MCL). (lu.se)
- BP-1002 is under development for the treatment of refractory/relapsed follicular lymphoma and other forms of Non-Hodgkin's lymphoma including diffuse large B-cell lymphoma, Waldenstrom macroglobulinemia, peripheral t-cell lymphomas, cutaneous t-cell lymphoma, extranodal marginal zone B-cell lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), mantle cell lymphoma, chronic lymphocytic leukemia (CLL), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), refractory, relapsed acute myeloid leukemia (AML) and solid tumor. (globaldata.com)
- B-lymphoblastic transformation of mantle cell lymphoma/leukemia with "double hit" changes. (bloodjournal.ru)
- Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. (bloodjournal.ru)
- SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib), the company's Bruton's tyrosine kinase inhibitor (BTKi), including two Supplemental New Drug Applications for treatment-naïve adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and Waldenström's macroglobulinemia (WM), and two Supplemental Applications for conversions from conditional approval to regular approval. (financialcontent.com)
- Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). (ashpublications.org)
- Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis. (yale.edu)
- Differentiating between low-grade lymphoma and reactive lymphocytes is often difficult by morphology alone as reactive lymphoid cells may acquire activation morphology from being exposed to different cytokines within the body fluid. (cytojournal.com)
- In large cell lymphoma and leukemia cells involvement of body fluid this concept becomes less challenging. (cytojournal.com)
- Large cell lymphoma and leukemia cells tend to have large size nuclei, less mature chromatin, and visible nucleoli with and without cytoplasmic vacuoles. (cytojournal.com)
- Intraocular lymphoma (IOL) is a rare lymphocytic malignancy. (medscape.com)
- What role do Bruton's tyrosine kinase inhibitors (BTKi's) play in the management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)? (managinglymphoma.com)
- In an analysis of the RESONATE trial, dose interruptions greater than one week reduced PFS among those taking ibrutinib for CLL or small lymphocytic lymphoma (SLL), but other studies have demonstrated no change in treatment efficacy among those requiring BTKi dose reductions due to concomitant CYP medications or increase post-transplant immunosuppression. (managinglymphoma.com)
- The investigators compiled a list of key genomic biomarkers in chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) from published and publicly available resources and established a comprehensive NGS panel for their analysis both in routine clinical practice and in biomedical research. (ceitec.eu)
- Caption: A schematic presentation of genomic targets and molecular markers integrated within the LYmphoid NeXt-generation sequencing (LYNX) panel design for the most common lymphoid malignant tumors (1 chronic lymphocytic leukemia, 2 mantle cell lymphoma, 3 follicular lymphoma, 4 diffuse large B-cell lymphoma, 5 acute lymphoblastic leukemia, and 6 Philadelphia chromosome-like acute lymphoblastic leukemia). (ceitec.eu)
- Final diagnosis 4 weeks later was lymphocytic lymphoma/chronic lymphocytic leukemia. (notifylibrary.org)
- Collantes R, Mazuecos A, Garcia T, Gomez-Bravo MA, Pascasio JM, Capote FJ, Castro P. Lymphocytic lymphoma/chronic lymphocytic leukemia in a solid-organ donor: an unestablished risk in elderly donors. (notifylibrary.org)
- 2. Clinical epidemiology - using data from the Swedish Lymphoma Registry to provide clinically useful real world data on treatment and prognosis, in many cases in collaboration with Nordic colleagues. (lu.se)
- Clinical lymphoma, myeloma & leukemia 2018 8 18 (11): 762-768. (cdc.gov)
- Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma. (cdc.gov)
- Leukemia & lymphoma 2019 6 60 (12): 2899-2908. (cdc.gov)
- ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. (cdc.gov)
- Leukemia & lymphoma 2019 Jan 1-9. (cdc.gov)
Multiple Myeloma2
- As the first and only standardized test authorized by the U.S. Food and Drug Administration (FDA) for MRD assessment in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL), Adaptive's clonoSEQ assay technology is the test of choice among drug developers. (adaptivebiotech.com)
- The clonoSEQ assay is the first and only FDA-cleared in vitro diagnostic (IVD) test service to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). (adaptivebiotech.com)
Refractory7
- Chimeric antigen receptor-modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. (nih.gov)
- Klepfish A, Gilles L, Ioannis K, Eliezer R, Ami S. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. (medscape.com)
- A low dose (approximately 1.5×10(5) cells per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. (nih.gov)
- Management of relapsed/refractory Chronic Lymphocytic Leukemia. (nih.gov)
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. (nih.gov)
- Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. (nih.gov)
- and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. (mboum.com)
Chronic lymphocyt5
- Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. (medscape.com)
- Nicoloso MS, Kipps TJ, Croce CM, Calin GA. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. (medscape.com)
- B Cell Development and Its Deregulation to Transformed States at the Pre-B Cell Receptor-Expressing Pre-BII Cell Stage -- Gene Expression Patterns in Human and Mouse B Cell Development -- New Insights into the Phenotype and Cell Derivation of B Cell Chronic Lymphocytic Leukemia -- Chronic Lymphocytic Leukemia: Molecular Genetics and Animal Models -- What Do Somatic Hypermutation and Class Switch Recombination Teach Us About Chronic Lymphocytic Leukaemia Pathogenesis? (epa.gov)
- Chronic Lymphocytic Leukaemia: A Review of the Immuno-architecture -- Clinical and Laboratory Parameters That Define Clinically Relevant B-CLL Subgroups -- Differential Effects on CLL Cell Survival Exerted by Different Microenvironmental Elements -- Genotypic Prognostic Markers -- Chronic Lymphocytic Leukaemia: Clinical Translations of Biological Features. (epa.gov)
- Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. (epa.gov)
Benefit for patients with lymphoid1
- Because this assay is straightforward and can also be used in research, it warrants further prospective testing in close cooperation among researchers, clinical hemato-oncologists, and hematopathologists to demonstrate its clinical utility and benefit for patients with lymphoid malignant tumors. (ceitec.eu)
Neoplasms3
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms. (medscape.com)
- El-Neanaey WA, Swelem RS, Ghallab OM, Mohamed Abu-Shelou S. Evaluation of CD160 and CD200 Expression as Differentiating Markers between Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms. (bdbiosciences.com)
- A new integrative, capture-based, next-generation sequencing (NGS) panel, LYmphoid NeXt-Generation Sequencing (LYNX), can detect and analyze standard and novel biomarkers in the most common lymphoid neoplasms simultaneously. (ceitec.eu)
Malignancy2
- T-cell acute lymphoblastic leukemia (T-ALL) is an uncommon, aggressive malignancy that rarely presents in the skin and is generally not considered as part of the differential diagnosis by dermatologists and dermatopathologists. (karger.com)
- A slow-growing, life-threatening and incurable cancer of adults, CLL is a type of mature B-cell malignancy in which abnormal leukemic B lymphocytes (a type of white blood cells) arise from the bone marrow and flood peripheral blood, bone marrow, and lymphoid tissues vi , vii , viii . (financialcontent.com)
Tissues5
- Leukemia starts in blood-forming tissues such as the bone marrow. (medlineplus.gov)
- Acute lymphoblastic leukemia (ALL) is a malignant expansion of lymphoblasts in the bone marrow, blood, and extramedullary tissues [ 1 ]. (karger.com)
- These fi ndings suggest that in human lymphoid tissues, blood cells, and lymphomas the lymphoid system plays a role in MCPyV infection and ( 17 - 20 ). (cdc.gov)
- Chronic lymphocytic leukemia (CLL) is a mature B cell neoplasm characterized by monoclonal proliferation and accumulation of B lymphocytes in the blood, bone marrow, and lymphoid tissues [ 1 ]. (biomedcentral.com)
- Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes in which these cells progressively accumulate in the bone marrow, blood, and lymphoid tissues. (nih.gov)
Oncology5
- Joseph M. Connors is a clinical professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the Clinical Director of the BC Cancer Agency Centre for Lymphoid Cancer. (genomebc.ca)
- Dr. Alina Gerrie is a hematologist and Assistant Professor in the Divisions of Hematology and Medical Oncology at the University of British Columbia (UBC) and a Clinician Investigator at the Centre for Lymphoid Cancer at BC Cancer. (bccrc.ca)
- CLL/SLL and WM patients are predominantly populated in the elderly, and there are increasing needs for improved efficacy and safety in CLL/SLL and WM treatments," said Professor Ma Jun, Director of the Harbin Institute of Hematology & Oncology, Chief Supervisor of Supervisory Committee at the Chinese Society of Clinical Oncology. (financialcontent.com)
- Journal Of Clinical Oncology 2023, 41: 7573-7573. (yale.edu)
- Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. (mboum.com)
Malignant4
- Lymphocytic infiltrates in the skin, both malignant and benign, can have overlapping clinical and histological features, presenting a diagnostic challenge. (karger.com)
- Recently, isolated human lymphoid malignant cells have been successfully grown outside of the patient after transplant into immune deficient mice (a "xenograft", or cross-species transplant). (rochester.edu)
- Non-Hodgkin Lymphomas Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the. (merckmanuals.com)
- Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of phenotypically mature malignant B lymphocytes. (merckmanuals.com)
Trials16
- A notable exception is mixed lineage leukemia rearranged infant ALL, where venetoclax largely recapitulates the activity of navitoclax, identifying this subgroup of patients as potential candidates for clinical trials of venetoclax in childhood ALL. (rti.org)
- She is a co-investigator on a Genome Canada Large-Scale Applied Research Project (LSARP) to advance personalized treatments of lymphoid cancer patients in collaboration with Drs. Christian Steidl and David Scott, and is a collaborator on a number of CIHR grants and industry-sponsored clinical trials. (bccrc.ca)
- Most new treatments are developed in clinical trials. (broomeoncology.com)
- Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. (broomeoncology.com)
- Clinical trials are available for most stages of cancer. (broomeoncology.com)
- Patients who are interested in participating in a clinical trial should discuss the risks and benefits of clinical trials with their physician. (broomeoncology.com)
- To ensure that you are receiving the optimal treatment of your cancer, it is important to stay informed and follow the cancer news in order to learn about new treatments and the results of clinical trials. (broomeoncology.com)
- The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases. (globaldata.com)
- With MOR208, our second proprietary compound enters clinical trials in addition to currently ten programs being developed in the clinic by our partners", commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. (rdworldonline.com)
- In clinical trials, BTKi discontinuation rates range from 5%-16%, but real-world studies suggest that this rate may be as high as 42%, with more than half (55%) of discontinuations due to adverse events (AEs). (managinglymphoma.com)
- NEW YORK (Reuters Health) - In patients with chronic lymphocytic leukemia (CLL), initial therapy with ibrutinib is among the factors that increase the likelihood of a complete response, according to pooled data from two trials. (medscape.com)
- 69.4% male) who had been treated with ibrutinib in the context of two clinical trials with follow-up lasting up to 55.6 months. (medscape.com)
- If clinical trials show that we can safely discontinue ibrutinib in some patients who achieve a CR, data in this article would suggest that patients without bulky lymphadenopathy who are treated in the front-line setting might be those likely to be able to discontinue ibrutinib. (medscape.com)
- To advance the field, we collaborate closely with clinicians to perform advanced molecular investigations of patient material derived from within and outside clinical trials, including sequencing, spatial omics technologies, serum protein profiling and functional screening. (lu.se)
- The evidence basis is primarily derived from clinical trials, but data can also be extracted from alternate sources such as national or regional data registries. (lu.se)
- Next, we will explore the possibility of combining clinical trials and registry data, by using registry infrastructure to conduct simplified randomized trials. (lu.se)
Cancers3
- Leukemia is a term for cancers of the blood cells. (medlineplus.gov)
- See Chronic Leukemias: 4 Cancers to Differentiate , a Critical Images slideshow, for images and information on CLL identification and treatment. (medscape.com)
- CD19 represents a particularly attractive immunotherapy target for cancers of lymphoid origin, due to its high expression levels on non-Hodgkin's lymphomas and B-cell leukemias such as chronic lymphocytic leukemia. (rdworldonline.com)
Immunology2
- Dr Turvey provides clinical care in the specialties of Clinical Immunology and Rheumatology, while his research program focuses on pediatric infectious and inflammatory diseases. (genomebc.ca)
- Clinical and Translational Immunology. (elsevierpure.com)
Myeloid3
- In the bone marrow, BL must be differentiated from B and T precursor and myeloid leukemias. (medscape.com)
- This phase I/II trial studies the side effects and best dose of bosutinib when given together with inotuzumab ozogamicin and to see how well it works in treating patients with acute lymphoblastic leukemia or chronic myeloid leukemia that has come back or does not respond to treatment. (survivornet.com)
- Giving bosutinib together with inotuzumab ozogamicin may be a better treatment for acute lymphoblastic leukemia or chronic myeloid leukemia. (survivornet.com)
Bone5
- Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). (wikipedia.org)
- When you have leukemia, your bone marrow makes large numbers of abnormal cells. (medlineplus.gov)
- Total marrow and lymphoid irradiation is a method of using IMRT to direct radiation to the bone marrow. (survivornet.com)
- Total marrow and lymphoid irradiation may allow a greater dose of radiation to be delivered to the bone marrow as a preparative regimen before hematopoietic cell transplant while causing less side effects to normal organs than standard total body irradiation. (survivornet.com)
- A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that express CD19. (nih.gov)
Patients with chronic lymphocy2
- Patients with chronic lymphocytic leukemia (chronic lymphoid leukemia, CLL) present with a wide range of symptoms and signs. (medscape.com)
- Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). (medscape.com)
Pathogenesis3
- In chronic lymphocytic leukemia the balance between the pro-apoptotic and anti-apoptotic members of the bcl-2 family is involved in the pathogenesis, chemorefractoriness and clinical outcome. (haematologica.org)
- Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition. (routledge.com)
- Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. (medscape.com)
Antigen5
- Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). (nih.gov)
- It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL). (nih.gov)
- The common acute lymphoblastic leukemia antigen (CD10)--emancipation from a functional enigma. (bdbiosciences.com)
- Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. (bdbiosciences.com)
- Human T-cell antigens defined by monoclonal antibodies: The 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. (bdbiosciences.com)
Reactive1
- We lack an in depth understanding of these cells, because they are not present in peripheral blood and are typically very rare in reactive lymphoid organs. (bvsalud.org)
Peripheral blood1
- Leukemic cell infiltration of the skin (i.e., leukemia cutis) typically occurs after the diagnosis of leukemia and may precede the appearance of leukemic blasts in the peripheral blood [ 2 ]. (karger.com)
Inhibitors2
- The new approvals of BRUKINSA for WM are based on data from ASPEN (NCT03053440), the first and only global Phase 3 head-to-head clinical trial of BTK inhibitors in WM. (financialcontent.com)
- Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors. (nih.gov)
Centre1
- Mel Krajden is the Medical Head of Hepatitis - Clinical Prevention Services and the Associate Medical Director of the Public Health Microbiology and Reference Laboratory and Head of Virology at the British Columbia Centre for Disease Control. (genomebc.ca)
Loci1
- Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. (medscape.com)
Rituximab1
- Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. (nih.gov)
Hematopoietic2
- This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. (survivornet.com)
- Well-illustrated and clinically focused, it details the basic science and clinical practice of hematology and hematopoietic cellular therapy-covering virtually all aspects of hematology in one definitive resource. (elsevierhealth.com)
Survival3
- Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. (medscape.com)
- Proliferation and survival of chronic lymphocytic leukemia (CLL) cells depend on microenvironmental signals coming from lymphoid organs. (uab.cat)
- The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival (summary by Quesada et al. (nih.gov)
Markers1
- Leukemia Markers. (bdbiosciences.com)
Neoplasm2
- Chronic lymphocytic leukemia (CLL) is a mature B cell neoplasm with a predilection for older individuals. (biomedcentral.com)
- Diagnosing hematolymphoid neoplasm by evaluating fine-needle aspiration (FNA) cytology sample is controversial and requires experience and clinical skills. (cytojournal.com)
Cells6
- Flow cytometry tests, which check for leukemia cells and identify which type of leukemia it is. (medlineplus.gov)
- The goals of treatment are to slow the growth of the leukemia cells and to give you long periods of remission. (medlineplus.gov)
- Engraftment of human chronic lymphocytic leukemia cells (hCD20+, brown) in an immune deficient mouse spleen showing typical follicle-like structures (arrows, Hemotoxylin and Eosin stain, H&E). (rochester.edu)
- MCPyV) can infect cells of the lymphoid system, we ana- remains to be identifi ed. (cdc.gov)
- The CD5 antibody, clone L17F12, is derived from the hybridization of NS-1/Ag4 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with human T-acute lymphoblastic leukemia (ALL) cells. (bdbiosciences.com)
- Human Leu T-cell differentiation antigens: quantitative expression on normal lymphoid cells and cell lines. (bdbiosciences.com)
Heterogeneity1
- Apart from the typical translocation t(11;14)(q13;q32) and more rare variants, such as t(2;11)(p11;q13) and t(11;22)(q13;q11), a considerable number of patients quite often show secondary molecular and chromosomal aberrations underlying heterogeneity of the clinical course of MCL. (bloodjournal.ru)
Treatments2
- What are the treatments for chronic lymphocytic leukemia (CLL)? (medlineplus.gov)
- Participation in a clinical trial may offer access to better treatments and advance the existing knowledge about treatment of this cancer. (broomeoncology.com)
Prognostic3
- In conclusion, we defined the prognostic power of bax/bcl-2 ratio, as determined by a flow cytometric approach, and highlighted a correlation with chemoresistance and outcome in chronic lymphocytic leukemia. (haematologica.org)
- Genomic profiling by NGS provides novel critical clinical information about prognostic and predictive biomarkers. (ceitec.eu)
- MRD status has strong prognostic value, and by integrating the measure into clinical studies our partners can more quickly and efficiently evaluate and advance novel therapeutics. (adaptivebiotech.com)
Lymphocytes2
- This subtype, termed chronic lymphocytic leukemia-type MBL (CLL-type MBL) is an asymptomatic, indolent, and chronic disorder in which people exhibit a mild increase in the number of circulating B-cell lymphocytes. (wikipedia.org)
- Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation of CD5CD23 B-cell lymphocytes. (haematologica.org)
Practice3
- Provides state-of-the-art guidance from global experts at the forefront of the latest research and clinical practice. (elsevierhealth.com)
- Medicare covers clonoSEQ in these four indications and is aligned with clinical practice guidelines which support assessing MRD at multiple time points throughout therapy to monitor treatment response and help predict patient outcomes. (adaptivebiotech.com)
- After statins were introduced into clinical practice, they were shown to have effects other than lipid lowering, referred to as pleiotropic effects (7). (cdc.gov)
Hematology2
- Wintrobe's Clinical Hematology (15th Edition). (yale.edu)
- Experts in research and clinical hematology, the editors are known worldwide for their contributions to the field. (digibookee.com)
Monoclonal2
- The only currently approved BH3-mimetic, the selective BCL2 inhibitor venetoclax, is highly efficacious in chronic lymphocytic leukemia and has rapidly advanced to an approved standard of care in frontline and relapsed disease in combination with anti-CD20 monoclonal antibodies. (biomedcentral.com)
- Zipf TF, Fox RI, Dilley J, Levy R. Definition of the high-risk acute lymphoblastic leukemia patient by immunological phenotyping with monoclonal antibodies. (bdbiosciences.com)
Phase2
- Will the drug transition to the next phase of its clinical pathway? (globaldata.com)
- We'll be collaborating with our new partner MorphoSys through Phase 1, and are sure that their antibody expertise and product development capabilities will help accelerate the compound's clinical progress. (rdworldonline.com)
Biopsies1
- We aimed to assess TdT staining in skin biopsies with similar-appearing lymphocytic infiltrates. (karger.com)
Potent1
Treatment5
- If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study and whether or not you have received earlier treatment for leukemia. (survivornet.com)
- Chronic Lymphocytic Leukemia Treatment (PDQ®): Health Professional Version. (medscape.com)
- Clinical studies have documented that the response rate to first re-treatment can be 70-80% with patients surviving an average of 3-5 years following CLL recurrence. (broomeoncology.com)
- Chronic lymphocytic leukemia that is resistant to treatment. (nih.gov)
- Oral oncolytic treatment for chronic lymphocytic leukemia. (nih.gov)
Molecular1
- He co-authored the first genetic privacy law in the US, was the prosecutions DNA expert in the OJ Simpson trial, and has been involved in a myriad of ancillary issues in the field of clinical molecular genetics. (genomebc.ca)
Laboratory1
- Clinical and Laboratory Standards Institute. (bdbiosciences.com)